Evidence map›Paper›PMID 39337700›Full record

ArticleInternational journal of molecular sciences2024

Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.

Fei Fei, Amar Jariwala, Sheeja Pullarkat, Eric Loo, Yan Liu, Parastou Tizro, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Andrew Artz and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Cohesin mutations and chromatin changes in cancer.International journal of cancer · 2026
    Review
  5. Epigenetic alterations in Myeloid Malignancies.Advances in experimental medicine and biology · 2026
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fei FeiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Amar JariwalaDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Sheeja PullarkatDepartment of Pathology, Division of Hematopathology, University of Los Angeles Medical Center, Los Angeles, CA 90095, USA.ORCID 0000-0003-1490-2374
Eric LooDepartment of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Yan LiuDepartment of Pathology and Laboratory Medicine, Loma Linda University Health, Loma Linda, CA 92350, USA.
Parastou TizroDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0002-9728-7292
Salman OtoukeshDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0002-7782-8805
Idoroenyi AmanamDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Andrew ArtzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Feras AllyDepartment of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA.
Milhan TelatarDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0001-5830-6158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accurate diagnosis and classification of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are challenging due to the overlapping pathological and molecular features of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). We investigated the genomic landscape in different MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 97), atypical chronic myeloid leukemia (aCML; n = 8), MDS/MPN-unclassified (MDS/MPN-U; n = 44), and MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 12). Our study indicated that MDS/MPN is characterized by mutations commonly identified in myeloid neoplasms, with

Indexed as

MutationMyelodysplastic-Myeloproliferative DiseasesProto-Oncogene ProteinsAdultAgedAged, 80 and overCarrier ProteinsCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsFemaleGenomicsHumansJanus Kinase 2Leukemia, Myelomonocytic, ChronicMaleASXL1 protein, humanCarrier ProteinsCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsJAK2 protein, humanJanus Kinase 2Nuclear ProteinsProto-Oncogene ProteinsRepressor ProteinsRNA Splicing FactorsSerine-Arginine Splicing FactorsSETBP1 protein, humanSRSF2 protein, humanTET2 protein, humangene mutationgenomicmyelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN)myeloid neoplasmnext-generation sequencing

Identifiers

PMID39337700
PMCPMC11431978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.